11.25.13
Dr. Ari Kellen has been appointed executive vice president and company group chairman at Valeant Pharmaceuticals International, Inc., effective January 1, 2014. He has also been named to Valeant’s executive management team.
Dr. Kellen was previously a senior partner in McKinsey & Company's Mid-Atlantic Office and has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies.
"The Board of Directors and I are pleased to include Ari as another strong addition to Valeant's senior management team," said J. Michael Pearson, chairman and chief executive officer. "Ari's broad experience in developing comprehensive growth strategies for health care companies will be invaluable to us as we continue to expand our successful growth trends. After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."
Dr. Kellen was previously a senior partner in McKinsey & Company's Mid-Atlantic Office and has led numerous strategy, organization and performance improvement studies for health care companies, including corporate strategies for boards and top management teams, business unit strategies for medical device, pharmaceutical and biotechnology, and health care services clients, and regional and country growth strategies.
"The Board of Directors and I are pleased to include Ari as another strong addition to Valeant's senior management team," said J. Michael Pearson, chairman and chief executive officer. "Ari's broad experience in developing comprehensive growth strategies for health care companies will be invaluable to us as we continue to expand our successful growth trends. After having worked with Ari for many years, I know that not only will he fit in well with the rest of the team, but he will be a strong advocate for the long-term shareholder focused culture at Valeant."